Q2 2026 saw strong revenue growth, robust U.S. commercial performance, and expanding international demand for VYJUVEK, despite flat European revenues due to German pricing accruals. The pipeline advanced with multiple registrational studies nearing readouts and a strong cash position supporting future growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.